F
Fred Poordad
Researcher at Cedars-Sinai Medical Center
Publications - 163
Citations - 11006
Fred Poordad is an academic researcher from Cedars-Sinai Medical Center. The author has contributed to research in topics: Ribavirin & Boceprevir. The author has an hindex of 44, co-authored 160 publications receiving 10590 citations. Previous affiliations of Fred Poordad include Johns Hopkins University & California Pacific Medical Center.
Papers
More filters
Journal ArticleDOI
Boceprevir for Previously Treated Chronic HCV Genotype 1 Infection
Bruce R. Bacon,Stuart C. Gordon,Eric Lawitz,Patrick Marcellin,John M. Vierling,Stefan Zeuzem,Fred Poordad,Zachary Goodman,Heather L. Sings,Navdeep Boparai,Margaret Burroughs,Clifford A. Brass,Janice K. Albrecht,Rafael Esteban +13 more
TL;DR: The addition of boceprevir to peginterferon-ribavirin resulted in significantly higher rates of sustained virologic response in previously treated patients with chronic HCV genotype 1 infection, as compared with pegintersfer on-off therapy alone.
Journal ArticleDOI
Rifaximin treatment in hepatic encephalopathy.
Nathan M. Bass,Kevin D. Mullen,Arun J. Sanyal,Fred Poordad,Guy W. Neff,Carroll B. Leevy,Samuel H. Sigal,Muhammad Y. Sheikh,Kimberly Beavers,Todd Frederick,Lewis W. Teperman,Donald J. Hillebrand,Shirley Huang,Kunal Merchant,Audrey L. Shaw,Enoch Bortey,William P. Forbes +16 more
TL;DR: Over a 6-month period, treatment with rifaximin maintained remission from hepatic encephalopathy more effectively than did placebo, and also significantly reduced the risk of hospitalization involving hepaticEncephalopathy.
Journal ArticleDOI
Response-guided Telaprevir Combination Treatment for Hepatitis C Virus Infection
Kenneth E. Sherman,Steven L. Flamm,Nezam H. Afdhal,David R. Nelson,Mark S. Sulkowski,Gregory T. Everson,Michael W. Fried,Michael Adler,Hendrik W. Reesink,M. Martin,Abdul J. Sankoh,Nathalie Adda,Robert S. Kauffman,Shelley George,Christopher I. Wright,Fred Poordad +15 more
TL;DR: Among patients with chronic HCV infection who had not received treatment previously, a regimen of peginterferon-ribavirin for 24 weeks, with telaprevir for the first 12 weeks, was noninferior to the same regimen for 48 weeks in patients with undetectable HCV RNA at weeks 4 and 12, with an extended rapid virologic response achieved in nearly two thirds of patients.
Journal ArticleDOI
Interleukin-28B Polymorphism Improves Viral Kinetics and Is the Strongest Pretreatment Predictor of Sustained Virologic Response in Genotype 1 Hepatitis C Virus
Alexander J. Thompson,Andrew J. Muir,Andrew J. Muir,Mark S. Sulkowski,Dongliang Ge,Jacques Fellay,Kevin V. Shianna,Thomas J. Urban,Nezam H. Afdhal,Ira M. Jacobson,Rafael Esteban,Fred Poordad,Eric Lawitz,Jonathan McCone,Mitchell L. Shiffman,Greg Galler,William M. Lee,Robert Reindollar,John W. King,Paul Y. Kwo,Reem Ghalib,B. Freilich,L. Nyberg,Stefan Zeuzem,Thierry Poynard,David M. Vock,Karen S. Pieper,Keyur Patel,Keyur Patel,Hans L. Tillmann,Hans L. Tillmann,Stephanie Noviello,Kenneth Koury,Lisa D. Pedicone,Clifford A. Brass,Janice K. Albrecht,David Goldstein,John G. McHutchison,John G. McHutchison +38 more
TL;DR: In treatment-naive HCV-1 patients treated with pegylated interferon and ribavirin, a polymorphism upstream of IL-28B is associated with increased on-treatment and sustained virologic response and effectively predicts treatment outcome.
Journal ArticleDOI
Entecavir treatment for up to 5 years in patients with hepatitis b e antigen-positive chronic hepatitis B
Ting-Tsung Chang,Ching-Lung Lai,Seung Kew Yoon,Samuel S. Lee,Henrique Sérgio Moraes Coelho,Flair José Carrilho,Fred Poordad,Waldemar Halota,Yves Horsmans,Naoky Tsai,Hui Zhang,Daniel J. Tenney,Ricardo Tamez,Uchenna H. Iloeje +13 more
TL;DR: Extended therapy with entecavir through 5 years maintained or increased rates of HBV DNA suppression and ALT normalization and the safety profile of entecvir was consistent with previous reports.